Understand the source comparison
Difference Between Cerebrolysin and P21: Comparison Table
This table maps the structural, regulatory, and practical distinctions that determine which compound fits specific research contexts. Each column reflects verified specifications rather than vendor marketing. Molecular Origin Porcine brain tissue enzymatic hyd
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table maps the structural, regulatory, and practical distinctions that determine which compound fits specific research contexts. Each column reflects verified specifications rather than vendor marketing.
- Molecular Origin
- Porcine brain tissue enzymatic hydrolysate
- Synthetic dipeptide (N-acetyl-Pro-Gly-Pro) from CNTF fragment
- Cerebrolysin is biologically derived; P21 is fully synthetic with defined structure
- Composition
- Mixture of peptides <10kDa + free amino acids; 30+ active components
- Single dipeptide sequence, MW 311.33 Da
- Cerebrolysin = complex cocktail; P21 = single molecule
- Primary Mechanism
- Multi-receptor neurotrophic activation (NGF, BDNF, GDNF, CNTF pathways)
- Selective BDNF mRNA upregulation via TrkB signaling
- Cerebrolysin acts broadly; P21 targets one pathway
- Administration Route
- Intramuscular or intravenous injection
- Intranasal spray or drops
- Cerebrolysin requires injection; P21 is non-invasive
- Regulatory Status
- Approved pharmaceutical in 50+ countries (Europe, Asia, Russia)
- Research chemical; no regulatory approval anywhere
- Cerebrolysin is prescription medication; P21 is research-only
- Clinical Trial Data
- 30+ published RCTs in stroke, dementia, TBI since 1990s
- Zero human clinical trials published as of 2026
- Cerebrolysin has decades of clinical evidence; P21 has none
- Typical Dosing
- 10–60mL/day IM for 10–28 days in clinical protocols
- 500–2000mcg intranasal daily in research settings
- Cerebrolysin uses higher volumes; P21 uses microgram doses
- Onset of Observable Effects
- 7–14 days (cumulative neurotrophic support)
- 2–6 hours (acute BDNF elevation)
- P21 acts faster; Cerebrolysin requires repeated dosing
- Half-Life
- Not established (complex mixture with variable peptide stability)
- Estimated 20–40 minutes intranasal; effects persist 6–12 hours
- P21 clears quickly but triggers sustained BDNF expression
- Storage Requirements
- Refrigerate 2–8°C; stable in sealed ampules 36 months
- Store lyophilized at −20°C; reconstituted at 2–8°C, use within 30 days
- Both require cold chain; Cerebrolysin has longer shelf stability
- Cost per Treatment Course
- $200–600 for 28-day clinical course (regional pricing variation)
- $80–150 for 30-day research supply (5mg total)
- P21 is substantially less expensive per course
- Primary Research Applications
- Stroke recovery, vascular dementia, traumatic brain injury, Alzheimer's disease
- Hippocampal neurogenesis, memory consolidation, nootropic research
- Cerebrolysin = clinical neuroprotection; P21 = cognitive enhancement research